Murlentamab  (Synonyms: 莫伦妥单抗; 3C23K; GM102)

Murlentamab (3C23K; GM102) is a humanized anti-AMHRII antibody. AMHRII is the anti-Müllerian hormone receptor. Murlentama significantly promotes macrophage-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Murlentama stimulates pro-inflammatory and anti-tumor internal environment, recruits and activates T cells. Murlentama suppresses tumors growth by inducing naïve macrophage orientation and promoting tumor-associated macrophage (TAM) reprogramming^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Humanized

AMHRII^[1]

Murlentamab (20 mg/kg；静脉注射；每周两次，持续 4 周) 在体内抑制小鼠肝癌 PDX 模型中的肿瘤生长^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

2058047-65-5

液体

Colorless to light yellow

莫伦妥单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• [1]. Prat M, et al. Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation. Cancers (Basel). 2021 Apr 13;13(8):1845.  [Content Brief]

  [2]. Barret JM, et al. The Expression of Anti-Müllerian Hormone Type II Receptor (AMHRII) in Non-Gynecological Solid Tumors Offers Potential for Broad Therapeutic Intervention in Cancer. Biology (Basel). 2021 Apr 7;10(4):305.  [Content Brief]